Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Solvay Reports Phase IIIb Creon Study Results
In the clinical study, children aged 7-11 years with EPI due to CF experienced an improved coefficient of fat absorption (CFA) during treatment with Creon, as compared to
In the clinical study, children aged 7-11 years with EPI due to CF experienced an improved coefficient of fat absorption (CFA) during treatment with Creon, as compared to
The Qiagen assay is designed to identify those patients whose tumors express the EGFRvIII mutation, allowing for the possibility of more targeted and personalised treatment. The company said
The phase I study titled, ‘A Phase I Open-Label Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of Single Intravitreal and Subconjunctival Doses of Palomid 529 in
Mr Fauchet has joined GSK from Sanofi Aventis where he worked as senior vice president for business development. He joined Sanofi in 1996, and headed up the Eastern
As per the agreement, Genmab is expected to receive an up-front license fee of $4.5m and will be entitled to milestones and royalties on sales of zanolimumab. TenX
MyoCell has been tested on patients in four clinical trials. TheRegen trial is designed to test the safety and effectiveness of a composition of muscle stem cells that
Reported sales in the quarter increased 15% to $12.5 billion, compared to reported sales in the same period last year. EBITDA on a pro forma basis, excluding certain
The product is the generic version of Caduet tablets, which combine the long-acting calcium channel blocker amlodipine besylate with the synthetic lipid-lowering agent atorvastatin calcium. Mylan claims that
Both the companies are negotiating an exclusive worldwide license that would result in Cannasat assuming product development and commercialisation rights to APL-130277 from Adagio in return for development
The company has also reported that it has designed a Phase 1/2 clinical trial to evaluate the safety of ARQ 197 administered in combination with irinotecan and cetuximab